Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial-POSCAL Study.

25-hydroxyvitamin D3 calcifediol clinical trial vitamin D deficiency young adults

Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
19 Jan 2024
Historique:
received: 22 12 2023
revised: 12 01 2024
accepted: 14 01 2024
medline: 26 1 2024
pubmed: 26 1 2024
entrez: 26 1 2024
Statut: epublish

Résumé

Vitamin D deficiency is highly prevalent, and recent evidence suggests a possible association between vitamin D deficiency and various health conditions. The aim of this study was to assess monthly calcifediol treatments for vitamin D deficiency (or biweekly, if the deficiency was severe) in a young adult population with no associated comorbidities. This multicentre phase I trial started with a four month open-label treatment phase (TP) that included 101 participants (65% women with mean age 29.8 years). Eighty-two percent of the subjects (79/96) achieved 25(OH)D levels within the target range (20-60 ng/mL) by the end of the TP, and they were subsequently randomised and subjected to a double-blind, placebo-controlled, five month follow-up phase (FP). At the end of the FP, 89% of participants maintained vitamin D levels of >20 ng/mL with calcifediol, versus 49% with placebo (

Identifiants

pubmed: 38276544
pii: nu16020306
doi: 10.3390/nu16020306
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Faes Farma (Spain)
ID : N/A

Auteurs

Pedro Guerra López (P)

Clinical Trials Unit, Pharmacology Department, Universidad Autónoma de Madrid, 28049 Madrid, Spain.

Mikel Urroz Elizalde (M)

Clinical Trials Unit, Pharmacology Department, Universidad Autónoma de Madrid, 28049 Madrid, Spain.
Clinical Pharmacology Service, Hospital Universitario La Paz, 28049 Madrid, Spain.

Noelia Vega-Gil (N)

Valdecilla Clinical Trials Unit, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.

Blanca Sánchez Santiago (B)

Valdecilla Clinical Trials Unit, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.

Iñaki Zorrilla Martínez (I)

Clinical Trials Unit, IIS BIOARABA, 01009 Vitoria-Gasteiz, Spain.
Mental Health and Childhood Research Group, IIS BIOARABA, 01009 Vitoria-Gasteiz, Spain.
Psychiatry Department, Araba University Hospital, 01009 Vitoria-Gasteiz, Spain.
Department of Neurosciences, University of the Basque Country UPV/EHU, 01006 Vitoria-Gasteiz, Spain.
CIBER of Mental Health (CIBERSAM), Institute of Health Carlos III, 28029 Madrid, Spain.

Mario Jiménez-Mercado (M)

Clinical Trials Unit, IIS BIOARABA, 01009 Vitoria-Gasteiz, Spain.

Esteban Jódar (E)

Department of Endocrinology and Nutrition, Quirónsalud Madrid University Hospital, 28233 Madrid, Spain.
School of Health Sciences, European University of Madrid, 28670 Madrid, Spain.

Araitz Landeta Manzano (A)

Medical Affairs, FAES FARMA S.A., 48940 Leioa, Spain.

Cristina Campo Hoyos (C)

Medical Affairs, FAES FARMA S.A., 48940 Leioa, Spain.

Jesús Frías Iniesta (J)

Clinical Trials Unit, Pharmacology Department, Universidad Autónoma de Madrid, 28049 Madrid, Spain.
Clinical Pharmacology Service, Hospital Universitario La Paz, 28049 Madrid, Spain.

Classifications MeSH